Welcome to Alpha-1 Awareness, a UK Charity that Supports people with AATD

AATD or Alpha-1 Antitrypsin Deficiency is a lack of the protein alpha-1 antitrypsin (AAT) which is produced in the liver. The main job of AAT is to protect the lungs. A deficiency can lead to life-threatening lung and/or liver disease.

The first signs and symptoms of lung disease caused by alpha-1 antitrypsin deficiency usually appear between ages 20 and 50.
The symptoms are:

  • shortness of breath following mild activity
  • reduced ability to exercise
  • wheezing

About ten percent of infants with the deficiency show signs of liver damage at birth. Fifteen percent of adult Alphas also develop liver disease.

Only a small fraction of alpha-1 antitrypsin deficient patients in the United Kingdom are aware of the causes of their condition.

Our charity is run by non-paid volunteers who all are either affected by Alpha-1 or have a family member who is. We all have a connection to Alpha-1 and this isn’t our day job. We have a real passion for the charity and for supporting people who are affected, their families and friends.

This website was created so that people can learn more about Alpha-1 and how to get support.  We produce our own booklets which people can download and view digitally (click here) and even request that a set be sent to them in the post for free. We have a private Facebook Group where we help to support people in a safe environment. If you would prefer one on one support, then you can email us directly on ‘support@alpha1.uk‘ or use our Contacts Us Form. We care, we want to help those affected, their families and their friends. We are also proud to be the only UK charity that is donating money to go directly to the research of a cure.

 

 


 

Fundraising

We would like to thank all those that raise funds for us, without you, we would not have a charity & we would not be able to support those affected with Alpha-1 and their families.
If you are wanting to help raise funds for our charity, please let us know by using our Contact Us form.


 Latest News

 

UK’s National Health Service Approves Daxas as Treatment for COPD

28th June 2017 –  The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, as a treatment for chronic obstructive pulmonary disease (COPD). The new indication
Read More

Kamada Withdraws MAA For Inhaled Alpha-1 Antitrypsin

23rd June 2017 –  Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the Company has withdrawn the Marketing Authorization Application (MAA) for its proprieta
Read More

Kamada Presents Updated Data from Phase 2 Clinical Trial of Inhaled Treatment of AAT

Previously announced top-line data from this trial indicated that patients treated with Kamada’s inhaled AAT demonstrated a significant increase in endothelial lining fluid (ELF), AAT antigenic and ANEC levels compared to the placebo group. The updat
Read More

Paul Amos’s Tandem Skydive raises over £1,200

We at Alpha-1 Awareness UK would like to say a big thank you to Paul Amos for the money that he has raised for us. As of the 15th May 2017, Paul has raised £1,201 (including Gift Aid) doing a tandem skydive on the 14th May 2017. “I’d like to raise as
Read More

BBC TV Show ‘Doctors’ to show Alpha-1 patient

    On the 8th May 2017 @ 13:45 on BBC 1, The TV Show ‘Doctors’ shows a family affected by Alpha-1 The episode is titled: Lizzie’s Last Stand It is not very often that we see Alpha-1 mentioned in a TV show, so this is excellent publ
Read More

Is Standard COPD Therapy Effective In Alpha-1 Antitrypsin Deficiency?

Intravenous augmentation may slow the progression of emphysema in patients with alpha-1 antitrypsin deficiency (AATD), but other treatment options for non-AATD-related chronic obstructive pulmonary disease (COPD) may not be effective in these patient
Read More

Z Factor, a Cambridge University spin-out, has raised £7 million to discover new drugs to fight Alpha-1

Z Factor, a Cambridge University spin-out, has raised £7 million to discover new drugs to fight liver and lung disease caused by a major gene defect. The Series A has been led by existing investor Medicxi. Cambridge Enterprise and Cambridge Innovatio
Read More

April 2017 Newsletter

Earlier this month we sent out to all of our charity members our latest Newsletter. In respect for all of our members, we did not make this public till we were sure that our members have received and had time to read it. I am pleased to say that it h
Read More

This website is run by Alphas and their carers. We do our very best to ensure that all information shown here is up-to-date and accurate. However, you should always consult your own GP or other medical professional if you have the slightest concerns about your health.